EA202090063A1 - COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA - Google Patents
COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIAInfo
- Publication number
- EA202090063A1 EA202090063A1 EA202090063A EA202090063A EA202090063A1 EA 202090063 A1 EA202090063 A1 EA 202090063A1 EA 202090063 A EA202090063 A EA 202090063A EA 202090063 A EA202090063 A EA 202090063A EA 202090063 A1 EA202090063 A1 EA 202090063A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- taupathia
- compositions
- methods
- taupathies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Предложены режимы дозирования и готовые формы антител против тау человека. Такие готовые формы и режимы дозирования находят применение в лечении таупатий, таких как прогрессирующий надъядерный паралич и болезнь Альцгеймера.Dosing regimens and ready-made forms of antibodies against human tau are proposed. Such formulations and dosage regimens find use in the treatment of taupathies such as progressive supranuclear palsy and Alzheimer's disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/037991 WO2018231254A1 (en) | 2017-06-16 | 2017-06-16 | Compositions and methods for treating tauopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090063A1 true EA202090063A1 (en) | 2020-04-03 |
Family
ID=59388133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090063A EA202090063A1 (en) | 2017-06-16 | 2017-06-16 | COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3638694A1 (en) |
JP (2) | JP2020529394A (en) |
KR (1) | KR20200018502A (en) |
CN (1) | CN110770253A (en) |
AU (1) | AU2017418317A1 (en) |
BR (1) | BR112019026298A2 (en) |
CA (1) | CA3064550A1 (en) |
EA (1) | EA202090063A1 (en) |
IL (1) | IL271256A (en) |
MX (1) | MX2019015071A (en) |
WO (1) | WO2018231254A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
HUE060258T2 (en) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunotherapy |
PE20190261A1 (en) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | ANTIBODIES THAT RECOGNIZE TAU |
CN110520440A (en) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | Anti- τ antibody and its application method |
MX2019013045A (en) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Antibodies recognizing tau. |
WO2020180819A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
CA3227440A1 (en) | 2021-07-27 | 2023-02-02 | Stand Therapeutics Co., Ltd. | Peptide tag and nucleic acid encoding same |
KR20230172262A (en) | 2022-06-15 | 2023-12-22 | 재단법인대구경북과학기술원 | Composition for preventing or treating tauopathy comprising PTK2 inhibitor as an active ingredient |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
CN102159204B (en) * | 2008-09-19 | 2015-04-01 | 辉瑞公司 | Stable liquid antibody formulation |
NZ609984A (en) * | 2010-10-11 | 2015-05-29 | Biogen Idec Internat Neuroscience Gmbh | Human anti-tau antibodies |
JP5941770B2 (en) | 2012-06-28 | 2016-06-29 | 株式会社ミマキエンジニアリング | Ink jet recording apparatus, liquid supply apparatus, and recording head cleaning method |
MX359817B (en) * | 2012-08-16 | 2018-10-11 | Ipierian Inc | Methods of treating a tauopathy. |
MX370723B (en) * | 2013-06-10 | 2019-12-20 | Ipierian Inc | Methods of treating a tauopathy. |
WO2015081085A2 (en) * | 2013-11-27 | 2015-06-04 | Ipierian, Inc. | Methods of treating a tauopathy |
EP3207061A1 (en) * | 2014-10-18 | 2017-08-23 | Pfizer Inc | Anti-il-7r antibody compositions |
-
2017
- 2017-06-16 WO PCT/US2017/037991 patent/WO2018231254A1/en active Application Filing
- 2017-06-16 EP EP17743107.9A patent/EP3638694A1/en not_active Withdrawn
- 2017-06-16 MX MX2019015071A patent/MX2019015071A/en unknown
- 2017-06-16 AU AU2017418317A patent/AU2017418317A1/en not_active Abandoned
- 2017-06-16 CN CN201780091913.0A patent/CN110770253A/en active Pending
- 2017-06-16 BR BR112019026298-9A patent/BR112019026298A2/en unknown
- 2017-06-16 CA CA3064550A patent/CA3064550A1/en active Pending
- 2017-06-16 EA EA202090063A patent/EA202090063A1/en unknown
- 2017-06-16 JP JP2019569225A patent/JP2020529394A/en active Pending
- 2017-06-16 KR KR1020197038545A patent/KR20200018502A/en not_active Application Discontinuation
-
2019
- 2019-12-08 IL IL271256A patent/IL271256A/en unknown
-
2021
- 2021-11-10 JP JP2021182954A patent/JP2022033757A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BR112019026298A2 (en) | 2020-07-14 |
KR20200018502A (en) | 2020-02-19 |
CA3064550A1 (en) | 2018-12-20 |
AU2017418317A1 (en) | 2019-12-05 |
MX2019015071A (en) | 2020-02-13 |
IL271256A (en) | 2020-01-30 |
WO2018231254A1 (en) | 2018-12-20 |
EP3638694A1 (en) | 2020-04-22 |
JP2022033757A (en) | 2022-03-02 |
JP2020529394A (en) | 2020-10-08 |
CN110770253A (en) | 2020-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090063A1 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA | |
CY1122265T1 (en) | ANTIBODIES AGAINST THEM AND THEIR USES | |
MX2022001755A (en) | Cyclic di-nucleotide compounds and methods of use. | |
MX2019007587A (en) | Ophthalmic composition for treatment of dry eye disease. | |
EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
EA202091480A1 (en) | AMINOINDOL COMPOUNDS SUITABLE AS TLR INHIBITORS | |
EA201691853A1 (en) | AGONISTS OF MUSCARINE RECEPTORS | |
EA201991447A1 (en) | VISCOSITY REDUCTION OF PHARMACEUTICAL COMPOSITIONS | |
EA201991029A1 (en) | MAGL INHIBITORS | |
EA201891609A1 (en) | DERIVATIVES 3 - ((HETERO-) ARYL) ALKYL-8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DECANE | |
EA201891608A1 (en) | DERIVATIVES OF 8-AMINO-2-OXO-1,3-DIAZASPIRO [4,5] DEAN | |
EA201891612A1 (en) | DERIVATIVES 3- (CARBOXYMETHYL) -8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DEAN | |
MX2022002635A (en) | Angiopoietin-like 4 antibodies and methods of use. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
EA201891610A1 (en) | DERIVATIVES 3- (CARBOXYETHYL) -8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DEAN | |
EA202190281A1 (en) | DERIVATIVES 3 - ((HETERO-) ARYL) -8-AMINO-2-OXO-1,3-DIAZA-SPIRO [4,5] DECANE | |
WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
EA202191515A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING APIXABAN | |
PH12018502139A1 (en) | Phosphaplatin liquid formulations | |
JOP20190286A1 (en) | Compositions and methods for treating tauopathies | |
TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
EA201990261A1 (en) | 2,5-DUB-SUBSTITUTED 3-METHYL-PYRASINES and 2,5,6-triple-substituted 3-METHYL-PYRASINES AS SHP2 ALLOSTERIC INHIBITORS | |
EA202090512A1 (en) | Pyrazolopyrimidinone compounds and their use | |
EA201991456A1 (en) | Bruton Imidazopyrazine Tyrosine Kinase Inhibitors | |
EA201892675A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ETHEPLIRSEN |